*EPISEEK analysis is only available through TruDiagnostic to registered healthcare provider partners.
You can sign up for a free clinician account here, to place patient orders and access results through our provider portal
When it comes to cancer, early detection is key to saving lives! With 610,000+ cancer deaths in the U.S. each year, most of which stemming from cancer types with no FDA-approved screening options, EPISEEK is making revolutionary strides in detecting cancers that have been previously undetectable in early stages.
The EPISEEK liquid biopsy blood test is intended to be used as a complementary tool to established cancer screening assessments. However in some cases, especially for cancer types that have no previously established screening test and are notoriously hard to detect, it may be the only warning sign currently available for providers.
Recent research from the University of Chicago shows that only 14% of cancers in the U.S. are diagnosed after the patient had a recommended screening test. This further highlights the value of a complementary tool like EPISEEK, that has higher sensitivity and specificity outputs.
COMPARE DETECTION ASSAYSMost appropriately licensed medical providers who care for patients and are located in the United States may order EPISEEK through TruDiagnostic's Healthcare Provider portal (free account sign up here).
Accepted licenses includes: MD, DO, DDS, DPM, OD, NP, DC, and PA.
Due to regulatory restrictions at this time, we are unable to offer EPISEEK testing to providers and their patients who are located in New York, or outside of the United States.
Place EPISEEK orders for your practice through your Healthcare Provider portal dashboard. (Provider pricing details can be found here)